{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:01:24Z","timestamp":1783573284238,"version":"3.55.0"},"reference-count":49,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Stand Up to Cancer-Genentech Catalyst Research Grant Award administered by the American Association for Cancer Research","award":["SU2C-AACR-CT1017"],"award-info":[{"award-number":["SU2C-AACR-CT1017"]}]},{"name":"Mayo Clinic Center for Clinical and Translational Science","award":["Award 92541640-2020\/Mayo Clinic"],"award-info":[{"award-number":["Award 92541640-2020\/Mayo Clinic"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,4,1]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVATE was designed to address whether a neoadjuvant combination of both targeted therapy and immunotherapy might leverage the benefits of each.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We tested neoadjuvant treatment with 12 weeks of vemurafenib, cobimetinib, and atezolizumab for patients with BRAF-mutated (BRAFm) melanoma (cohort A) and cobimetinib and atezolizumab for patients with BRAF-wild-type (BRAFwt) melanoma (cohort B), regimens which we have shown generate a substantial major pathological response. After therapeutic lymph node dissection, patients received 24 weeks of adjuvant atezolizumab. Here, we report survival outcomes and their association with biomarkers assayed among the gut microbiome and peripheral blood immune subsets.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>With 49 months median follow-up, the median RFS was not reached for cohort A and was 40.8 months for cohort B. At 24 months after operation, 2 of 14 cohort A patients and 4 of 13 cohort B patients had experienced distant relapse. Key findings from correlative analyses included diversity, taxonomic and functional metagenomic gut microbiome signals associated with distant metastasis-free survival at 2 years. Notably, we observed a strong correlation between low microbial arginine biosynthesis (required for T-cell activation and effector function) and early distant recurrence (p=0.0005), which correlated with taxonomic differential abundance findings. Peripheral blood immune monitoring revealed increased double-positive (CD4+CD8+) T cells in patients with early recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Neoadjuvant treatment with cobimetinib and atezolizumab\u00b1vemurafenib was associated with a low rate of distant metastasis in patients with high-risk stage III melanoma. Freedom from early distant metastasis was highly associated with taxonomic differences in gut microbiome structure and with functional pathway alterations known to modulate T cell immunity. Identification of predictive biomarkers will permit optimization of neoadjuvant therapy regimens for individual patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03554083\">NCT03554083<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2025-011706","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T21:05:31Z","timestamp":1744751131000},"page":"e011706","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03554083","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03554083","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03554083","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-4219","authenticated-orcid":false,"given":"Matthew S","family":"Block","sequence":"first","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0709-1155","authenticated-orcid":false,"given":"Garth D","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-5624","authenticated-orcid":false,"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0685-9863","authenticated-orcid":false,"given":"Stephen","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5234-3190","authenticated-orcid":false,"given":"Lu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5691-8249","authenticated-orcid":false,"given":"Thomas James","family":"Flotte","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-7975","authenticated-orcid":false,"given":"Eric P","family":"Grewal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-5040","authenticated-orcid":false,"given":"Robert R","family":"McWilliams","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-2619","authenticated-orcid":false,"given":"Lisa A","family":"Kottschade","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-554X","authenticated-orcid":false,"given":"Evidio","family":"Domingo-Musibay","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-4325","authenticated-orcid":false,"given":"Svetomir N","family":"Markovic","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-3305","authenticated-orcid":false,"given":"Anastasios","family":"Dimou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-4767","authenticated-orcid":false,"given":"Heather N","family":"Montane","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-8258","authenticated-orcid":false,"given":"Mara A","family":"Piltin","sequence":"additional","affiliation":[{"name":"Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-0562","authenticated-orcid":false,"given":"Daniel L","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-4990","authenticated-orcid":false,"given":"Samir S","family":"Khariwala","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2628-0720","authenticated-orcid":false,"given":"Jane Yuet Ching","family":"Hui","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-1542","authenticated-orcid":false,"given":"Courtney L","family":"Erskine","sequence":"additional","affiliation":[{"name":"Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7820-6138","authenticated-orcid":false,"given":"Carrie A","family":"Strand","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0529-5146","authenticated-orcid":false,"given":"David","family":"Zahrieh","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5782-2983","authenticated-orcid":false,"given":"Haidong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-8692","authenticated-orcid":false,"given":"Tina J","family":"Hieken","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2025100313312684000_13.4.e011706.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"2025100313312684000_13.4.e011706.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0198-0"},{"key":"2025100313312684000_13.4.e011706.3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"key":"2025100313312684000_13.4.e011706.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0197-1"},{"key":"2025100313312684000_13.4.e011706.5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature New Biol"},{"key":"2025100313312684000_13.4.e011706.6","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390614","article-title":"Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift","volume":"43","author":"Hieken","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100313312684000_13.4.e011706.7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100313312684000_13.4.e011706.8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025100313312684000_13.4.e011706.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.024"},{"key":"2025100313312684000_13.4.e011706.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45798-8","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial","volume":"15","author":"Hieken","year":"2024","journal-title":"Nat Commun"},{"key":"2025100313312684000_13.4.e011706.11","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.21105\/joss.06830","article-title":"sourmash v4: A multitool to quickly search, compare, and analyze genomic and metagenomic data sets","volume":"9","author":"Irber","year":"2024","journal-title":"JOSS"},{"key":"2025100313312684000_13.4.e011706.12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65088","article-title":"Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3","volume":"10","author":"Beghini","year":"2021","journal-title":"Elife"},{"key":"2025100313312684000_13.4.e011706.13","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12198","article-title":"Struo2: efficient metagenome profiling database construction for ever-expanding microbial genome datasets","volume":"9","author":"Youngblut","year":"2021","journal-title":"PeerJ"},{"key":"2025100313312684000_13.4.e011706.14","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts342"},{"key":"2025100313312684000_13.4.e011706.15","doi-asserted-by":"publisher","DOI":"10.2307\/2680104"},{"key":"2025100313312684000_13.4.e011706.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-022-02655-5","article-title":"LinDA: linear models for differential abundance analysis of microbiome compositional data","volume":"23","author":"Zhou","year":"2022","journal-title":"Genome Biol"},{"key":"2025100313312684000_13.4.e011706.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009442","article-title":"Multivariable association discovery in population-scale meta-omics studies","volume":"17","author":"Mallick","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2025100313312684000_13.4.e011706.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"2025100313312684000_13.4.e011706.19","doi-asserted-by":"publisher","DOI":"10.2307\/2670170"},{"key":"2025100313312684000_13.4.e011706.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30151-2"},{"key":"2025100313312684000_13.4.e011706.21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.annonc.2024.05.002","article-title":"Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma","volume":"35","author":"Menzies","year":"2024","journal-title":"Ann Oncol"},{"key":"2025100313312684000_13.4.e011706.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03077-5"},{"key":"2025100313312684000_13.4.e011706.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01188-3"},{"key":"2025100313312684000_13.4.e011706.24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108"},{"key":"2025100313312684000_13.4.e011706.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.08.004"},{"key":"2025100313312684000_13.4.e011706.26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236"},{"key":"2025100313312684000_13.4.e011706.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290"},{"key":"2025100313312684000_13.4.e011706.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0672-4","article-title":"Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients","volume":"11","author":"Peters","year":"2019","journal-title":"Genome Med"},{"key":"2025100313312684000_13.4.e011706.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01695-5"},{"key":"2025100313312684000_13.4.e011706.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02803-3"},{"key":"2025100313312684000_13.4.e011706.31","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","article-title":"Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome","volume":"28","author":"Simpson","year":"2022","journal-title":"Nat Med"},{"key":"2025100313312684000_13.4.e011706.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.10.007"},{"key":"2025100313312684000_13.4.e011706.33","doi-asserted-by":"crossref","unstructured":"Usyk M , Hayes RB , Knight R , et al . Gut microbiome is associated with recurrence-free survival in patients with resected stage iiib-d or stage iv melanoma treated with immune checkpoint inhibitors. bioRxiv [Preprint] 2024. doi:10.1101\/2024.04.16.589761","DOI":"10.1101\/2024.04.16.589761"},{"key":"2025100313312684000_13.4.e011706.34","doi-asserted-by":"crossref","DOI":"10.3390\/nu15020316","article-title":"Fecal and Tissue Microbiota Are Associated with Tumor T-Cell Infiltration and Mesenteric Lymph Node Involvement in Colorectal Cancer","volume":"15","author":"Luu","year":"2023","journal-title":"Nutrients"},{"key":"2025100313312684000_13.4.e011706.35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/01635581.2017.1263750","article-title":"Intestinal Proportion of Blautia sp. is Associated with Clinical Stage and Histoprognostic Grade in Patients with Early-Stage Breast Cancer","volume":"69","author":"Luu","year":"2017","journal-title":"Nutr Cancer"},{"key":"2025100313312684000_13.4.e011706.36","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41418-021-00784-1","article-title":"Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment","volume":"28","author":"Terrisse","year":"2021","journal-title":"Cell Death Differ"},{"key":"2025100313312684000_13.4.e011706.37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00906","article-title":"The Genus Alistipes: Gut Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health","volume":"11","author":"Parker","year":"2020","journal-title":"Front Immunol"},{"key":"2025100313312684000_13.4.e011706.38","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00607-8","article-title":"Gut microbiota and metabolites signatures of clinical response in anti-PD-1\/PD-L1 based immunotherapy of biliary tract cancer","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark Res"},{"key":"2025100313312684000_13.4.e011706.39","doi-asserted-by":"crossref","DOI":"10.3390\/nu15092211","article-title":"Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota","volume":"15","author":"Fusco","year":"2023","journal-title":"Nutrients"},{"key":"2025100313312684000_13.4.e011706.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.12.003"},{"key":"2025100313312684000_13.4.e011706.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24331-1","article-title":"Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer","volume":"12","author":"Luu","year":"2021","journal-title":"Nat Commun"},{"key":"2025100313312684000_13.4.e011706.42","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.annonc.2022.07.001","article-title":"Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors","volume":"33","author":"Peyraud","year":"2022","journal-title":"Ann Oncol"},{"key":"2025100313312684000_13.4.e011706.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04003-2"},{"key":"2025100313312684000_13.4.e011706.44","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0721"},{"key":"2025100313312684000_13.4.e011706.45","article-title":"Unsaturated Fatty Acids and Their Immunomodulatory Properties","volume":"12","author":"Coniglio","year":"2023","journal-title":"Biology (Basel)"},{"key":"2025100313312684000_13.4.e011706.46","first-page":"3985","article-title":"Multi-omics characterization of the unsaturated fatty acid biosynthesis pathway in colon cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2025100313312684000_13.4.e011706.47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250991","article-title":"CD40L confers helper functions to human intra-melanoma class-I-restricted CD4+CD8+ double positive T cells","volume":"5","author":"Parrot","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100313312684000_13.4.e011706.48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00622"},{"key":"2025100313312684000_13.4.e011706.49","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212169","article-title":"Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions","volume":"219","author":"Schad","year":"2022","journal-title":"J Exp Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-011706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:31:37Z","timestamp":1759523497000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-011706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/jitc-2025-011706"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-011706","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}